Best GLP-1 Side Effect Tracker Apps for 2026
6 min read
CEO & Co-Founder of miora. Consumer health growth expert.
The single most predictable thing about a GLP-1 protocol is that the side effects show up in patterns - and the single most common mistake is logging them in a way that does not surface the pattern until after the protocol has already been adjusted. This roundup walks the tools that actually catch side-effect drift early, what to track, and how miora handles the daily check without an app to open.
Topics on this page
Nausea is the visible early side effect; mood and energy drift at month three is the one that quietly ends most protocols. Both need daily logging.
The injection-day pattern is the most useful single piece of data. Nausea typically peaks 24-48 hours after the shot; without that mapping you are guessing about the dose.
Hydration and food intake are not direct side effects but they are the strongest amplifiers. A tracker that ignores them misses the most actionable lever.
The first eight weeks on a GLP-1 - tirzepatide, semaglutide, retatrutide - look fairly similar from the outside. Some nausea, some fatigue, weight starts moving. The interesting part starts in week eight to twelve, when the side-effect profile shifts. Nausea recedes, mood and energy patterns become the dominant signal, and the people most likely to abandon the protocol are the ones who never had a daily log to surface the trend. This guide is the honest list of what to track, the apps actually built for it, and what miora does conversationally in iMessage.
The list of GLP-1 side effects is long. The list of side effects that actually matter for dose decisions is short. Six things, each on a daily 1-to-5 scale, capture the entire actionable signal.
Nausea. The most visible side effect and the one most likely to drive an early dose drop. Track time-of-day and severity, not just presence-or-absence.
Fatigue. Distinct from sleep quality. Fatigue on a GLP-1 often spikes for two days after the injection then recedes, regardless of how you slept.
GI changes. Constipation, diarrhea, reflux, bloating. The pattern across the cycle is the data, not the daily binary.
Hydration. Daily ounces or liters. The strongest amplifier of every other side effect; dehydration makes nausea, fatigue, and constipation worse simultaneously.
Food intake quality. Not calories - quality. Are you hitting protein? Fiber? Or is the appetite suppression letting you skip the inputs that prevent the side effects in the first place?
Mood and energy. The six-dimension subset (energy, drive, libido, anhedonia) from the symptom rubric guide. Catches the slow drift that nausea-only trackers miss.
Any tracker that captures only the first one (nausea log on an app) is solving 15% of the problem. The pattern is in the full set.
The single most predictable feature of GLP-1 side effects is the injection-day curve. For most users on weekly tirzepatide or semaglutide, the curve looks something like: injection on day 0, nausea peaks day 1-2, energy dips day 2-3, recovery by day 4-5, baseline by day 6 just before the next shot. The shape varies by individual but the pattern is real and repeatable.
The pattern matters because it tells you whether the next dose escalation is going to be tolerable. A protocol that has nausea at a 3-out-of-5 on day 2 of week 8 will probably tolerate the next titration. A protocol that has nausea at 4-out-of-5 on day 3 - meaning the curve is widening, not just spiking - is signaling that the current dose is the ceiling. Without daily data mapped to injection day, this decision is a guess.
The pattern also tells you when split dosing is worth considering. Some users find that splitting a weekly tirzepatide dose into two half-doses 3-4 days apart flattens the side-effect curve. Whether that works depends on whether your individual curve is spiky (helped by splitting) or flat (not). You need a month of daily data mapped to injection day to know which one you are.
Most GLP-1 tracker apps are built for the first eight weeks. The first eight weeks are the easy weeks - nausea is loud, the signal is obvious, the data is binary enough that a habit-tracker UI works. The protocol gets interesting at month three.
At month three, the nausea has usually receded. Weight is still coming off but slower. The new signals are: mood drift (the anhedonia and flat-affect pattern the community surfaces in long threads), sleep architecture changes (deep sleep often dips on GLP-1s for reasons that are not fully understood), and the food-quality drift (appetite is suppressed enough that protein intake silently drops below 1.6 g/kg lean body mass). None of these are in the nausea log.
The trackers that survive month three are the ones that broadened the daily check before the side-effect profile broadened. Adding the mood rubric in month three is too late - the baseline data is missing. miora's six-dimension daily rubric starts in week one for exactly this reason: by month three, the baseline is locked and the drift is detectable.
The hardest thing about side-effect tracking is not the logging. It is the cross-reference. A nausea score of 3 on day 2 means one thing if your hydration log shows 32 oz of water; it means a different thing if it shows 80 oz. A 2-out-of-5 anhedonia score on a week your sleep averaged 6.5 hours with 45 minutes of deep is a different signal than the same score on a week of normal sleep.
Most generic symptom apps treat each entry as standalone. They will show you a calendar of nausea scores or a trend line of fatigue. They will not show you that your worst nausea weeks all correlate with sub-50-oz hydration days, or that your worst fatigue spikes happened in weeks when training volume was 30% above average. The cross-reference is where the actionable information lives, and it requires a tracker that ingests data from multiple sources - injection log, daily symptom check, wearable for sleep and HRV, hydration, food - and aggregates them in one place.
This is the structural reason miora is built as an iMessage agent rather than an app. The same thread that captures the dose captures the symptom check, ingests the wearable summary, and pulls in the food log. The cross-reference happens automatically because everything lives in one record.
The four most common GLP-1 surfaces in 2026 have different practical tracking needs.
Mounjaro (tirzepatide for type 2 diabetes). Pen-delivered, fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg). Tracking is straightforward; the patient knows the dose because it is on the pen. The dual GIP/GLP-1 mechanism produces a slightly different side-effect profile than pure GLP-1 agonists - typically less nausea, more variability in fatigue.
Wegovy (semaglutide for weight loss). Pen-delivered, fixed titration schedule (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly). The titration pace is what users most often log against; missing a titration week or staying at a step longer than the standard is a meaningful tracker note.
Zepbound (tirzepatide for weight loss). Same compound as Mounjaro, different branding and indication. Pen-delivered, same dose steps. Tracking is identical to Mounjaro.
Compound semaglutide or tirzepatide. Vial-and-syringe, units calculated from concentration. This is where the tracker burden is highest because the dose math is on the user. Reconstitution date, vial concentration, and units-per-dose all need to be logged - and dose drift over a multi-month cycle is the single most common error. The peptide tracker requirements guide covers the dose calculation in more detail.
The daily flow is one text in the evening: 'GLP day-of-week check: nausea / fatigue / GI / hydration oz / protein g / mood 1-5?' A typical reply is something like '2 3 OK 64 130 3' or in prose: 'nausea mild, fatigue moderate, GI fine, 64 oz water, hit protein, mood normal.' miora parses both formats and logs the dimensions.
The weekly summary is where the cross-reference happens. The text might read: 'Side-effect trend: nausea averaging 2.2 day 1-2 post-injection, recovering by day 4. Fatigue spike correlates with sub-60oz hydration days; the two worst fatigue scores both happened on 40-something oz days. Mood and energy are stable. Net: dose tolerance looks good; hydration is the lever for next two weeks.'
The summary does the interpretation that an app's chart view requires you to do yourself. Most people will not. The trend surfaces itself or it does not get used.
Side-effect logs become clinically useful when the conversation with the prescriber starts with structured data instead of a vague complaint. Thresholds worth flagging:
Nausea at 4-out-of-5 for more than two consecutive cycles. Worth discussing dose adjustment or split dosing.
Mood drift at -1 from baseline for two weeks at stable dose. Especially anhedonia. See the mood rubric guide.
Protein intake below 1.6 g/kg lean body mass for three weeks. Combined with weight loss this is a muscle-loss risk. See muscle preservation on GLP-1.
GI changes that persist past the first month at a stable dose. Constipation that needs more than baseline fiber and water is often a dose-related signal.
Resting heart rate trending up 5+ bpm over two weeks without a training-load explanation. Worth a labs check.
The prescriber conversation goes faster with a four-week chart than with 'I have been feeling off.' miora can generate a clinician-ready summary on request.
Two boundaries worth being explicit about.
This guide does not promise specific weight loss outcomes or specific timelines. GLP-1 responses vary individually and depend on dose, compliance, food intake, training, sleep, and a dozen other factors. The right tracker helps you run a better protocol, not a different protocol.
miora also does not prescribe or recommend any GLP-1, any compounding pharmacy, any dose, or any titration schedule. All clinical decisions belong with your prescriber. miora's job is to surface the daily and weekly trends so that the next clinician conversation starts with structured data instead of a complaint. This content is for informational purposes only and is not medical advice. GLP-1 medications require clinician supervision and prescription.
96
